Evidence map›Paper›PMID 37251789›Full record

ReviewThe Lancet regional health. Europe2023

The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint.

Linus Jönsson, Anders Wimo, Ron Handels, Gunilla Johansson, Mercè Boada, Sebastiaan Engelborghs, Lutz Frölich, Frank Jessen, Patrick Gavin Kehoe, Milica Kramberger and 6 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet regional health. Europe, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 2 pooled it
65.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Prevalence of high-risk plasma p-tau217 levels and 5-year transition of risk status in 70-year-olds.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. The Tetrapeptide HAEE Promotes Amyloid-Beta Clearance from the Brain.International journal of molecular sciences · 2025
    Article
  18. Review
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 12 countries.

Linus JönssonDepartment of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden.
Anders WimoDepartment of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden.
Ron HandelsDepartment of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden.
Gunilla JohanssonDepartment of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden.
Mercè BoadaACE Alzheimer Center Barcelona - International University of Catalunya, Spain & Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain.
Sebastiaan EngelborghsDepartment of Neurology and Bru-BRAIN, Center for Neurosciences, UZ Brussel & Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Lutz FrölichDepartment of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany.
Frank JessenDepartment of Psychiatry, University of Cologne, Faculty of Medicine & University Hospital Cologne, Cologne, Germany.
Patrick Gavin KehoeDepartment of Neurology, University Medical Centre, Ljubljana & Medical Faculty, University of Ljubljana, Slovenia.
Milica KrambergerBristol Medical School, Institute of Medical Science, Bristol, UK.
Alexandre de MendonςaFaculty of Medicine, University of Lisbon, Lisbon, Portugal.
Pierre Jean OussetDepartment of Internal Medicine and Clinical Gerontology, Toulouse University Hospital, Toulouse, France.
Nikolaos ScarmeasDepartment of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Pieter Jelle VisserDepartment of Psychiatry and Neuropsychology, University of Maastricht & Department of Neurology, Amsterdam Centre, Amsterdam, the Netherlands.
Gunhild WaldemarDepartment of Neurology, Danish Dementia Research Centre, Copenhagen University Hospital -Rigshospitalet, Copenhagen, Denmark.
Bengt WinbladDepartment of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden.
Karolinska Institutet · SEAt Bristol · GBHeidelberg University · DEInstituto de Salud Carlos III · ESKarolinska University Hospital · SENational and Kapodistrian University of Athens · GRUniversité Fédérale de Toulouse Midi-Pyrénées · FRUniversity of Cologne · DEUniversity of Copenhagen · DKUniversity of Lisbon · PTUniversity of Ljubljana · SIVrije Universiteit Brussel · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lecanemab, an anti-amyloid antibody with effects on biomarker and clinical endpoints in early Alzheimer's Disease (AD), was granted accelerated approval by the FDA in 2023 and regulatory review in Europe is ongoing. We estimate the population potentially eligible for treatment with lecanemab in the 27 EU countries to 5.4 million individuals. Treatment costs would exceed 133 billion EUR per year if the drug is priced similarly as in the United States, amounting to over half of the total pharmaceutical expenditures in the EU. This pricing would be unsustainable; the ability to pay for high-priced therapies varies substantially across countries. Pricing similarly to what has been announced for the United States may place the drug out of reach for patients in some European countries. Disparities in access to novel amyloid-targeting agents may further deepen the inequalities across Europe in health outcomes. As representatives of the European Alzheimer's Disease Consortium Executive Committee, we call for pricing policies that allow eligible patients across Europe to access important innovations, but also continued investments in research and development. Infrastructure to follow up the usage of new therapies in routine care and new payment models may be needed to address affordability and inequalities in patient access.

Indexed as

Antibodies against amyloid b-peptideHealth economicsLecanemabMild ADPassive immunotherapyPricingProdromal AD

Identifiers

PMID37251789
PMCPMC10220264
OpenAlexW4377195480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.